Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Sali, Arpana ^a   Guerron, Alfredo D ^a   Gordish Dressman, Heather ^a   Spurney, Christopher F ^c   Iantorno, Micaela ^a   Hoffman, Eric P ^a,b   Nagaraju, Kanneboyina ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; GLUCOCORTICOID; PREDNISOLONE; PREDNISONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL ISOLATION; CONTROLLED STUDY; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; GRIP STRENGTH; HEART DISEASE; HEART MUSCLE; HEART MUSCLE FIBROSIS; IN VITRO STUDY; LONGITUDINAL STUDY; MOTOR COORDINATION; MOUSE; MUSCLE CONTRACTION; MUSCLE STRENGTH; NONHUMAN; SKELETAL MUSCLE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG SCREENING; FIBROSIS; HAND STRENGTH; HEART; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PHYSIOLOGY; STANDARD; TIME;

MUS;

ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; DRUG EVALUATION, PRECLINICAL; DYSTROPHIN; FEMALE; FIBROSIS; GLUCOCORTICOIDS; HAND STRENGTH; HEART; MICE; MICE, INBRED MDX; MOTOR ACTIVITY; MUSCLE CONTRACTION; MUSCLE, SKELETAL; MYOCARDIUM; REFERENCE STANDARDS; TIME FACTORS;

EID: 84859258298     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034204     Document Type: Article

References (29)

1. Manzur AY, Kuntzer T, Pike M, Swan A, (2008) Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev.
2. Wong BL, Christopher C, (2002) Corticosteroids in Duchenne muscular dystrophy: a reappraisal. J Child Neurol 17: 183-190.
3. Hudecki MS, Pollina CM, Granchelli JA, Daly MK, Byrnes T, et al. (1993) Strength and endurance in the therapeutic evaluation of prednisolone-treated MDX mice. Res Commun Chem Pathol Pharmacol 79: 45-60.
4. Griggs RC, Moxley RT, 3rd, Mendell JR, Fenichel GM, Brooke MH, et al. (1993) Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 43: 520-527.
5. Golumbek PT, Keeling RM, Connolly AM, (2007) Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout. Neuromuscul Disord 17: 376-384.
6. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, et al. (2009) Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 39: 591-602.
7. Spurney CF, Knoblach S, Pistilli EE, Nagaraju K, Martin GR, et al. (2008) Dystrophin-deficient cardiomyopathy in mouse: Expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscul Disord 18: 371-381.
8. Guerron AD, Rawat R, Sali A, Spurney CF, Pistilli E, et al. (2010) Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy. PLoS One 5: e11220.
9. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, et al. (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704-1708.
10. Keeling RM, Golumbek PT, Streif EM, Connolly AM, (2007) Weekly oral prednisolone improves survival and strength in male mdx mice. Muscle Nerve 35: 43-48.
11. Lefaucheur JP, Pastoret C, Sebille A, (1995) Phenotype of dystrophinopathy in old mdx mice. Anat Rec 242: 70-76.
12. Granchelli JA, Pollina C, Hudecki MS, (2000) Pre-clinical screening of drugs using the mdx mouse. Neuromuscul Disord 10: 235-239.
13. Yang L, Luo J, Petrof BJ, (1998) Corticosteroid therapy does not alter the threshold for contraction-induced injury in dystrophic (mdx) mouse diaphragm. Muscle Nerve 21: 394-397.
14. Bauer R, Straub V, Blain A, Bushby K, MacGowan GA, (2009) Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur J Heart Fail 11: 463-471.
15. Skrabek RQ, Anderson JE, (2001) Metabolic shifts and myocyte hypertrophy in deflazacort treatment of mdx mouse cardiomyopathy. Muscle Nerve 24: 192-202.
16. Marques MJ, Oggiam DS, Barbin IC, Ferretti R, Santo Neto H, (2009) Long-term therapy with deflazacort decreases myocardial fibrosis in mdx mice. Muscle Nerve 40: 466-468.
17. Rotundo IL, Faraso S, De Leonibus E, Nigro G, Vitiello C, et al. (2011) Worsening of cardiomyopathy using deflazacort in an animal model rescued by gene therapy. PLoS One 6: e24729.
18. Freishtat RJ, Nagaraju K, Jusko W, Hoffman EP, (2009) Glucocorticoid efficacy in asthma: is improved tissue remodeling upstream of anti-inflammation. J Investig Med 58: 19-22.
19. Bushby K, Muntoni F, Urtizberea A, Hughes R, Griggs R, (2004) Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Neuromuscul Disord 14: 526-534.
20. DeSilva S, Drachman DB, Mellits D, Kuncl RW, (1987) Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit. Arch Neurol 44: 818-822.
21. Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA, (2001) Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr 138: 45-50.
22. Balaban B, Matthews DJ, Clayton GH, Carry T, (2005) Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil 84: 843-850.
23. Biggar WD, Harris VA, Eliasoph L, Alman B, (2006) Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 16: 249-255.
24. Silversides CK, Webb GD, Harris VA, Biggar DW, (2003) Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 91: 769-772.
25. Markham LW, Spicer RL, Khoury PR, Wong BL, Mathews KD, et al. (2005) Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol 26: 768-771.
26. Houde S, Filiatrault M, Fournier A, Dube J, D'Arcy S, et al. (2008) Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 38: 200-206.
27. Bauer R, Macgowan GA, Blain A, Bushby K, Straub V, (2008) Steroid treatment causes deterioration of myocardial function in the {delta}-sarcoglycan-deficient mouse model for dilated cardiomyopathy. Cardiovasc Res 79: 652-661.
28. Hartel JV, Granchelli JA, Hudecki MS, Pollina CM, Gosselin LE, (2001) Impact of prednisone on TGF-beta1 and collagen in diaphragm muscle from mdx mice. Muscle Nerve 24: 428-432.
29. Weller B, Massa R, Karpati G, Carpenter S, (1991) Glucocorticoids and immunosuppressants do not change the prevalence of necrosis and regeneration in mdx skeletal muscles. Muscle Nerve 14: 771-774.